Peacock Tariff Consulting is the North American tariff specialist for London-based U.K. exporters selling into the U.S. and Canada. We work with luxury and fashion brands, pharma, whisky, and finance-driven goods exporters. Independent, fluent in U.S. Section 122 and Section 232 frameworks, and equipped to model the Canada-routing math under CETA + CUSMA.
Post-Brexit, the U.K. is a unique trade jurisdiction – not EU, not U.S., not CPTPP. Every British SME exporting to the U.S. needs specialist tariff advice, and very few firms are marketing themselves on U.K. SEO with a cross-Atlantic story. Peacock Tariff Consulting is the North American advisor U.K. exporters call when their U.S. buyer says “EU reciprocal tariffs are hitting us – can you use CUSMA instead by routing through Canada?”
We are not a U.K. customs broker; we do not pretend to be. We are the tariff consultant who knows how the U.S. and Canada will actually treat a U.K. shipment.
The London exporter U.K. wedge
London is where U.K. exporters make tariff decisions. Burberry, Mulberry, Dr. Martens, AstraZeneca, GSK, Diageo all have tariff strategy set here. Heathrow handles the highest-value U.K. air cargo to the U.S. A London advisory page that explicitly addresses U.S. tariffs for U.K. exporters has minimal SEO competition and direct commercial value.
U.S. reciprocal tariffs post-Brexit
Section 122 (15% surcharge until July 24, 2026) applies to most U.K. goods. Post-expiration, the picture depends on Congressional action and Section 232 sectoral expansions. For U.K. luxury and pharma exporters, scenario modeling is the standard advisory deliverable.
Heathrow HTS – high-value air freight
Heathrow handles £200B+ in annual air freight, much of it U.S.-bound. High-value goods (luxury, pharma, precision instruments) face HTS classification questions where small differences move duty meaningfully.
Luxury brand playbook – first-sale and Section 122
U.K. luxury brands selling into the U.S. can use First Sale for Export valuation to drop dutiable value 15-30%. Section 122 still applies on top, but on a reduced base. For mid-market U.K. luxury houses ($25M-$200M U.S. revenue), the math is meaningful.
Pharma Section 232 – what London boards should know
Section 232 pharma effective July 31, 2026 with tiered rates. Generics and biosimilars excluded; branded patented drugs covered. AstraZeneca, GSK, and U.K.-based specialty pharma face direct exposure on U.S.-bound branded products.
Whisky U.S. tariff scenarios
Scotch whisky U.S. tariff treatment varies. Currently MFN plus Section 122 unless USMCA-routed (which is generally not feasible for U.K.-distilled whisky). Brexit-era U.S.-U.K. tariff dynamics make whisky a recurring sensitivity point.
Routing via Canada – when CETA + CUSMA layering pays
For some U.K. products, routing through Canada (CETA preferential into Canada, then CUSMA-eligible into the U.S. if substantial transformation occurs in Canada) can reduce U.S. duty exposure. Eligibility depends on the product and the Canadian-side processing. Most luxury and finished goods will not qualify; specific industrial inputs and components sometimes do.
Frequently asked questions
Do you provide U.K.-side customs broker services?
No. We are not a U.K. customs broker. We are the North American tariff specialist your U.K. customs broker calls when your U.S. customer has tariff questions.
How does First Sale work for U.K. luxury brands?
If your U.K. brand sells through a middleman to the U.S. importer, First Sale lets the customs value be the manufacturer-to-middleman price, dropping U.S. dutiable value 15-30%. Documentation requirements are technical; we set up programs and review existing claims.
Can U.K. exports route through Canada to avoid U.S. Section 122?
Sometimes. For products that undergo substantial transformation in Canada or qualify under specific CUSMA rules, the math can work. For finished goods (luxury, pharma, finished food), it generally does not. We model case-by-case.
How does Section 232 pharma affect U.K. exporters?
Branded patented drugs face the new tariff effective July 31, 2026 with tiered rates. Generics and biosimilars are excluded. U.K.-based AstraZeneca, GSK, and similar firms are directly affected.
Are you affiliated with British American Business or any U.K. chamber?
No. We are independent.
Get started
Book a London exporter U.S. tariff review.